Providing Appropriate Risk Information on Genome Editing for Patients

被引：17

作者：

Araki, Motoko ^{[1
]}

Ishii, Tetsuya ^{[1
]}

机构：

[1] Hokkaido Univ, Off Hlth & Safety, Sapporo, Hokkaido 0600808, Japan

来源：

TRENDS IN BIOTECHNOLOGY | 2016年 / 34卷 / 02期

基金：

日本学术振兴会;

关键词：

IN-VIVO; T-CELLS; NUCLEASES; THERAPY;

D O I：

10.1016/j.tibtech.2015.12.002

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Genome editing, represented by CRISPR/Cas9, facilitates somatic and germline gene modifications in many species, including humans. However, one of key issues, off target mutation deserves special consideration prior to clinical applications. We herein discuss the importance of risk information on genome editing for obtaining legitimate patient consent and social acceptance.

引用

收藏

页码：86 / 90

页数：5

相关论文

共 20 条

[1]

Caution required for handling genome editing technology [J].

Araki, Motoko ;

Nojima, Kumie ;

Ishii, Tetsuya .

TRENDS IN BIOTECHNOLOGY, 2014, 32 (05) :234-237

[2]

Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases [J].

Bloom, Kristie ;

Ely, Abdullah ;

Mussolino, Claudio ;

Cathomen, Toni ;

Arbuthnot, Patrick .

MOLECULAR THERAPY, 2013, 21 (10) :1889-1897

[3]

Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases [J].

Cho, Seung Woo ;

Kim, Sojung ;

Kim, Yongsub ;

Kweon, Jiyeon ;

Kim, Heon Seok ;

Bae, Sangsu ;

Kim, Jin-Soo .

GENOME RESEARCH, 2014, 24 (01) :132-141

[4]

Multiplex Genome Engineering Using CRISPR/Cas Systems [J].

Cong, Le ;

Ran, F. Ann ;

Cox, David ;

Lin, Shuailiang ;

Barretto, Robert ;

Habib, Naomi ;

Hsu, Patrick D. ;

Wu, Xuebing ;

Jiang, Wenyan ;

Marraffini, Luciano A. ;

Zhang, Feng .

SCIENCE, 2013, 339 (6121) :819-823

[5]

RIKEN suspends first clinical trial involving induced pluripotent stem cells [J].

Garber, Ken .

NATURE BIOTECHNOLOGY, 2015, 33 (09) :890-891

[6]

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 [J].

Hacein-Bey-Abina, Salima ;

Garrigue, Alexandrine ;

Wang, Gary P. ;

Soulier, Jean ;

Lim, Annick ;

Morillon, Estelle ;

Clappier, Emmanuelle ;

Caccavelli, Laure ;

Delabesse, Eric ;

Beldjord, Kheira ;

Asnafi, Vahid ;

Macintyre, Elizabeth ;

Dal Cortivo, Liliane ;

Radford, Isabelle ;

Brousse, Nicole ;

Sigaux, Francois ;

Moshous, Despina ;

Hauer, Julia ;

Borkhardt, Arndt ;

Belohradsky, Bernd H. ;

Wintergerst, Uwe ;

Velez, Maria C. ;

Leiva, Lily ;

Sorensen, Ricardo ;

Wulffraat, Nicolas ;

Blanche, Stephane ;

Bushman, Frederic D. ;

Fischer, Alain ;

Cavazzana-Calvo, Marina .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (09) :3132-3142

[7]

ICH, 2009, ICH CONS GEN PRINC A

[8]

Germline genome-editing research and its socioethical implications [J].

Ishii, Tetsuya .

TRENDS IN MOLECULAR MEDICINE, 2015, 21 (08) :473-481

[9]

Standards needed for gene-editing errors [J].

Joung, J. Keith .

NATURE, 2015, 523 (7559) :158-158

[10]

Kim D, 2015, NAT METHODS, V12, P237, DOI [10.1038/NMETH.3284, 10.1038/nmeth.3284]